Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05179005 · ClinicalTrials.gov registry record

RibFix Advantage™ Post-Market Follow-Up

A clinical trial, sponsored by Zimmer Biomet.

Terminated
Registry status
1
Enrollment target

NCT05179005: Clinical Trial study, sponsored by Zimmer Biomet.

NCT05179005 is a clinical trial that was terminated before completion, run by Zimmer Biomet. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05179005 was terminated before completion, sponsored by Zimmer Biomet.

TERMINATED
Registry status
1 participants
Enrollment target

Study Summary

To confirm safety, performance, and clinical benefits for the use of RibFix Advantage™ in the fixation, stabilization, and fusion of rib fractures and osteotomies of normal and osteoporotic bone

Primary Outcome

Number of subjects who needed surgical re-intervention related to rib fracture repair

Interventions

  • DEVICE RibFix Advantage

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2023-04-20
Est. Completion 2023-12-31
Zimmer Biomet

115 total trials

Why NCT05179005 stopped before completion

NCT05179005 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which RibFix Advantage is the first listed.

NCT05179005 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05179005 about?

NCT05179005 is a clinical study titled "RibFix Advantage™ Post-Market Follow-Up". To confirm safety, performance, and clinical benefits for the use of RibFix Advantage™ in the fixation, stabilization, and fusion of rib fractures and osteotomies of normal and osteoporotic bone

What is the current status of trial NCT05179005?

This trial is currently terminated. The enrollment target is 1 participants. The study started on 2023-04-20. Estimated completion is 2023-12-31.

What interventions are being tested in trial NCT05179005?

The interventions under investigation include: RibFix Advantage (DEVICE).

Who is sponsoring clinical trial NCT05179005?

This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05179005, the US trial registry maintained by the National Library of Medicine. NCT05179005 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.